REG - Allergy Therapeutics - PDMR Dealings & Shareholding Update

Allergy TherapeuticsAnnouncement

12/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260312:nRSL3113Wa&default-theme=true

RNS Number : 3113W  Allergy Therapeutics PLC  12 March 2026

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

PDMR Dealings & Shareholding Update

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy immunotherapies, announces that
the Company has been notified by ZQ Group of the following.

 

A re-organisation took place within ZQ Group which involved the transfer of
the majority of the Company's shares previously held by SkyGem Acquisition
Limited to SkyGem International Holdings Limited, both entities being within
ZQ Group (the "Transfer"). The Transfer was undertaken to optimise ZQ's
internal holding structure of AGY shares. The Transfer did not result in any
change to the ultimate beneficial ownership of Allergy Therapeutics plc.

 

Separately, SkyGem International Holdings Limited placed an aggregate of
209,600,000 shares to four investors at an average price of 10 pence per
share. The shares placed are in the paper form and are restricted from trading
in the AIM market within the twelve months following the placement. The
placement was designed to optimise the shareholder base ahead of the Company's
earlier announced plan of a potential dual listing in Hong Kong.

 

Following these transactions, ZQ Capital and related entities hold the
following shares in Allergy Therapeutics plc:

 

 Holding entity                     Number of shares
 SkyGem International Holdings Ltd  3,828,575,524
 SkyGem Acquisition Ltd             2,150,665
 ZQ Capital Ltd                     315,343
 Shen Zheqing                       90,000
 Total                              3,831,131,532

The aggregate holdings above represent 60.5% of the Company's issued share
capital.

 

As a result of these transactions, Zheqing (Simon) Shen, a person discharging
managerial responsibilities ("PDMR") by virtue of his position as a director
of the Company, has notified the Company of the following dealings.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please
see www.allergytherapeutics.com (http://www.allergytherapeutics.com/) .

 Notification and public disclosure of transactions by Director/persons
discharging managerial responsibilities ("PDMR") and persons closely
associated with them ("PCA")

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         ZQ Capital Management Limited
 2   Reason for the notification
 a)  Position/status                                              Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy
                                                                  Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification.
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics Plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares

 b)  Nature of the transaction                                    (1)  Transfers between SkyGem Acquisition Ltd to SkyGem International
                                                                  Holdings Ltd

                                                                  (2)  Transfers between SkyGem Acquisition Ltd to SkyGem UK Holding Ltd

                                                                  (3)  Transfers between SkyGem UK Holding Ltd to SkyGem International Holdings
                                                                  Ltd

                                                                  (4)  Sale of Ordinary Shares

 c)  Price(s) and volume(s)                                       Price(s)                                  Volume(s)

                                                                  (1)  £0.1080                              (1)  150,925,926

                                                                  (1)  £0.0228                              (1)  1,993,473,455

                                                                  (2)  £0.0228                              (2)  1,893,776,143

                                                                  (3)  £0.0228                              (3)  1,893,776,143

                                                                  (4)  $0.1087                              (4)  1,840,000

                                                                  (4)  £0.1020                              (4)  189,334,000

                                                                  (4)  $0.1086                              (4)  3,684,000

                                                                  (4)  $0.1085                              (4)  14,742,000

 d)  Aggregated information                                       (1)   2,144,399,381 Ordinary Shares

     ·       - Aggregated volume                                  (2)   1,893,776,143 Ordinary Shares

     ·       - Price                                              (3)   1,893,776,143 Ordinary Shares

                                                                  (4)   209,600,000 Ordinary Shares

                                                                  (1)  £0.0288 per share

                                                                  (2)  £0.0228 per share

                                                                  (3)  £0.0228 per share

                                                                  (4)  £0.100 per share
 e)  Date of the transaction                                      (1) 25/02/2026

                                                                  (2) 25/02/2026

                                                                  (3) 25/02/2026

                                                                  (4) 27/02/2026, 27/02/2026, 02/03/2026, 27/02/2026

 f)  Place of the transaction                                     Outside a trading venue.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDDGDXUGBDGLB



            Copyright 2019 Regulatory News Service, all rights reserved